BR112021008204A2 - novas composições de proteínas racionalmente projetadas - Google Patents
novas composições de proteínas racionalmente projetadas Download PDFInfo
- Publication number
- BR112021008204A2 BR112021008204A2 BR112021008204-2A BR112021008204A BR112021008204A2 BR 112021008204 A2 BR112021008204 A2 BR 112021008204A2 BR 112021008204 A BR112021008204 A BR 112021008204A BR 112021008204 A2 BR112021008204 A2 BR 112021008204A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- fusion protein
- fact
- antibody
- polypeptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752293P | 2018-10-29 | 2018-10-29 | |
| US62/752,293 | 2018-10-29 | ||
| US201962811116P | 2019-02-27 | 2019-02-27 | |
| US62/811,116 | 2019-02-27 | ||
| PCT/CN2019/114026 WO2020088459A1 (en) | 2018-10-29 | 2019-10-29 | Novel rationally designed protein compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021008204A2 true BR112021008204A2 (pt) | 2021-08-10 |
Family
ID=70462528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021008204-2A BR112021008204A2 (pt) | 2018-10-29 | 2019-10-29 | novas composições de proteínas racionalmente projetadas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12378295B2 (https=) |
| EP (1) | EP3873945A4 (https=) |
| JP (1) | JP7496091B2 (https=) |
| KR (1) | KR20210087965A (https=) |
| CN (1) | CN113166272B (https=) |
| AU (1) | AU2019371994A1 (https=) |
| BR (1) | BR112021008204A2 (https=) |
| CA (1) | CA3117853A1 (https=) |
| MX (1) | MX2021004916A (https=) |
| SG (1) | SG11202104297XA (https=) |
| TW (1) | TWI840433B (https=) |
| WO (1) | WO2020088459A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| MX2021002077A (es) * | 2018-08-20 | 2021-05-27 | 1Globe Biomedical Co Ltd | Nuevas composiciones de anticuerpos para la inmunoterapia contra el cáncer. |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| IL298136A (en) | 2020-05-13 | 2023-01-01 | Bonum Therapeutics Inc | Preparations of protein complexes and methods of using them |
| EP4174088A4 (en) * | 2020-06-30 | 2024-01-24 | GI Innovation, Inc. | FUSION PROTEIN COMPRISING AN ANTI-LAG-3 AND IL-2 ANTIBODY AND USE THEREOF |
| US20230242607A1 (en) * | 2020-07-09 | 2023-08-03 | Eutilex Co., Ltd. | Il-2 variants |
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| AU2022306974A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| AU2023226512A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
| CN120518765A (zh) * | 2025-02-08 | 2025-08-22 | 龙启生物科技(上海)有限公司 | 一种结合人CD8β的VHH及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| SG192673A1 (en) * | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| RU2769282C2 (ru) * | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| CN107915777A (zh) * | 2016-10-09 | 2018-04-17 | 泰州迈博太科药业有限公司 | 一种重组免疫细胞因子及其应用 |
| MY201482A (en) * | 2017-04-03 | 2024-02-26 | Hoffmann La Roche | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| JP7148539B2 (ja) * | 2017-04-03 | 2022-10-05 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 免疫抱合体 |
-
2019
- 2019-10-29 TW TW108139140A patent/TWI840433B/zh active
- 2019-10-29 AU AU2019371994A patent/AU2019371994A1/en not_active Abandoned
- 2019-10-29 SG SG11202104297XA patent/SG11202104297XA/en unknown
- 2019-10-29 US US17/288,273 patent/US12378295B2/en active Active
- 2019-10-29 BR BR112021008204-2A patent/BR112021008204A2/pt not_active IP Right Cessation
- 2019-10-29 JP JP2021547634A patent/JP7496091B2/ja active Active
- 2019-10-29 CA CA3117853A patent/CA3117853A1/en active Pending
- 2019-10-29 WO PCT/CN2019/114026 patent/WO2020088459A1/en not_active Ceased
- 2019-10-29 EP EP19878076.9A patent/EP3873945A4/en active Pending
- 2019-10-29 CN CN201980071932.6A patent/CN113166272B/zh active Active
- 2019-10-29 KR KR1020217016193A patent/KR20210087965A/ko not_active Abandoned
- 2019-10-29 MX MX2021004916A patent/MX2021004916A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3873945A1 (en) | 2021-09-08 |
| SG11202104297XA (en) | 2021-05-28 |
| EP3873945A4 (en) | 2022-12-28 |
| JP2022512043A (ja) | 2022-02-01 |
| WO2020088459A1 (en) | 2020-05-07 |
| TW202035440A (zh) | 2020-10-01 |
| CA3117853A1 (en) | 2020-05-07 |
| CN113166272A (zh) | 2021-07-23 |
| MX2021004916A (es) | 2021-06-18 |
| US20210388049A1 (en) | 2021-12-16 |
| KR20210087965A (ko) | 2021-07-13 |
| CN113166272B (zh) | 2024-07-23 |
| JP7496091B2 (ja) | 2024-06-06 |
| AU2019371994A1 (en) | 2021-06-03 |
| US12378295B2 (en) | 2025-08-05 |
| TWI840433B (zh) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021008204A2 (pt) | novas composições de proteínas racionalmente projetadas | |
| US11851484B2 (en) | Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof | |
| CN113227146B (zh) | 密蛋白18.2结合部分和其用途 | |
| CN114206932B (zh) | 修饰的双特异性抗cd3抗体 | |
| JP2024059872A (ja) | 新規抗ｃｃｒ８抗体 | |
| ES2915410T3 (es) | Anticuerpo contra LAG-3, fragmento de unión a antígeno del mismo y aplicación farmacéutica del mismo | |
| KR102709815B1 (ko) | 인간 cd3 결합 항체 | |
| CN114380912B (zh) | 结合cd47的抗体治疗剂 | |
| JP7352973B2 (ja) | 二重特異性抗体及びその使用 | |
| JP2023098966A (ja) | 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 | |
| US12441795B2 (en) | Anti-ROR1 antibodies and preparation method and uses thereof | |
| TW202019971A (zh) | 抗間皮素抗體 | |
| JP6574257B2 (ja) | 新規の抗Ｎｏｄａｌ抗体及びその使用方法 | |
| EP3041868A2 (en) | Cd70-binding peptides and method, process and use relating thereto | |
| BR112014001573B1 (pt) | Molécula fv ao antígeno multivalente | |
| CN114981301B (zh) | Pd1和vegfr2双结合剂 | |
| WO2016207402A1 (en) | Proteins comprising a mutated lair-1 fragment and uses thereof | |
| TW202204391A (zh) | 一種SIRPα-Fc融合蛋白 | |
| CN117222672A (zh) | 抗cldn4-抗cd137双特异性抗体 | |
| US20220289825A1 (en) | FUSION PROTEIN TARGETING PD-L1 AND TGF-ß AND USE THEREOF | |
| BR112021003182A2 (pt) | novas composições de anticorpo para imunoterapia contra o câncer | |
| BR112021005670A2 (pt) | polipeptídeos tetraméricos de ligação a her2 | |
| US20250129175A1 (en) | CDC Platform Antibody | |
| WO2026042803A1 (ja) | がん治療におけるプラチナ系薬剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 | |
| TW202547885A (zh) | 抗體、抗體藥物偶聯物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2853 DE 09-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |